ASH 2023 | Testing for BCR::ABL kinase mutations in CML and how they impact TKi resistance

Simona Soverini • 8 Dec 2023

ASH 2023

Simona Soverini, PhD, University of Bologna, Bologna, Italy, highlights the importance of testing for BCR::ABL kinase mutations in chronic myeloid leukemia (CML) and discusses how they impact resistance to tyrosine kinase inhibitors (TKis). She mentions traditional single-cell sequencing methods of mutational testing, as well as more developed next-generation sequencing (NGS) and digital polymerase chain reaction (PCR). Guidelines for how to conduct mutational testing can be found in the European LeukemiaNet manuscript. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.